Intellectual Property

Signpath has in-licensed agreements including patent applications with three universities for intravenous and subcutaneous formulations of curcumin;

• Liposomal curcumin - MD Anderson Cancer Center
• Polymeric nanocurcumin - Johns Hopkins Cancer Center
• Extended-release PLGA-curcumin - University of North Texas Health Science Center

The U.S. Patent and Trade Office has returned office action on all three applications and a patent for liposomal curcumin was issued on June 28, 2011.

Preclinical toxicological study in dogs with liposomal curcumin revealed dose-dependant hemolysis which prompted a method to mitigate this. A provisional patent was submitted November 2009.

Additional Submissions to the USPTO:

• Preclinical toxicological study in dogs with liposomal curcumin revealed dose-dependant hemolysis which prompted a method to mitigate this: provisional patent was submitted November 2009.
• Curcumin for Post Traumatic Stress Disorder, Progressive Supranuclear Palsy, Parkinson’s disease, Alzheimer’s disease and related neuropathologic conditions.
• Comparison of pure synthesized curcumin verses mixtures of curcuminoids from the tumeric plant extracts.
• A patent to mitigate adverse reactions from conventional anti-diabetic drugs.
• A patent to mitigate cardiotoxicity “LQTS” from curcumin and other drugs.
• Lipocurc is a registered trademark.